NCT00095264View on ClinicalTrials.gov

A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

October 31, 2004

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Darbepoetin Alfa

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY